393 related articles for article (PubMed ID: 25033434)
1. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer.
Devkar TB; Tekade AR; Khandelwal KR
Colloids Surf B Biointerfaces; 2014 Oct; 122():143-150. PubMed ID: 25033434
[TBL] [Abstract][Full Text] [Related]
2. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Ondansetron Hydrochloride-Loaded Nanostructured Lipid Carriers Using Solvent Injection Method for Enhancement of Pharmacokinetic Properties.
Duong VA; Nguyen TT; Maeng HJ; Chi SC
Pharm Res; 2019 Jul; 36(10):138. PubMed ID: 31350675
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation.
Joshi AS; Patel HS; Belgamwar VS; Agrawal A; Tekade AR
J Mater Sci Mater Med; 2012 Sep; 23(9):2163-75. PubMed ID: 22802103
[TBL] [Abstract][Full Text] [Related]
5. Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics.
Wavikar P; Pai R; Vavia P
J Pharm Sci; 2017 Dec; 106(12):3613-3622. PubMed ID: 28923321
[TBL] [Abstract][Full Text] [Related]
6. Agranulocytosis-Protective Olanzapine-Loaded Nanostructured Lipid Carriers Engineered for CNS Delivery: Optimization and Hematological Toxicity Studies.
Gadhave DG; Tagalpallewar AA; Kokare CR
AAPS PharmSciTech; 2019 Jan; 20(1):22. PubMed ID: 30604305
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery.
Wavikar PR; Vavia PR
J Liposome Res; 2015; 25(2):141-9. PubMed ID: 25203610
[TBL] [Abstract][Full Text] [Related]
8. Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin.
Chanburee S; Tiyaboonchai W
Drug Dev Ind Pharm; 2017 Mar; 43(3):432-440. PubMed ID: 27808665
[TBL] [Abstract][Full Text] [Related]
9. Formulation of intranasal surface engineered nanostructured lipid carriers of rotigotine: Full factorial design optimization, in vitro characterization, and pharmacokinetic evaluation.
Zafar A; Awad Alsaidan O; Alruwaili NK; Sarim Imam S; Yasir M; Saad Alharbi K; Singh L; Muqtader Ahmed M
Int J Pharm; 2022 Nov; 627():122232. PubMed ID: 36155794
[TBL] [Abstract][Full Text] [Related]
10. Nasal administration of ondansetron using a novel microspheres delivery system.
Mahajan HS; Gattani SG
Pharm Dev Technol; 2009; 14(2):226-32. PubMed ID: 19519195
[TBL] [Abstract][Full Text] [Related]
11. Coated Lipidic Nanoparticles as a New Strategy for Enhancing Nose-to-Brain Delivery of a Hydrophilic Drug Molecule.
Salem LH; El-Feky GS; Fahmy RH; El Gazayerly ON; Abdelbary A
J Pharm Sci; 2020 Jul; 109(7):2237-2251. PubMed ID: 32320670
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima-based microspheres.
Suryawanshi SR; Thakare NP; More DP; Thombre NA
Drug Deliv; 2015; 22(7):894-902. PubMed ID: 24279581
[TBL] [Abstract][Full Text] [Related]
13. Formulation and Characterization of Nanostructured Lipid Carriers of Rizatriptan Benzoate-Loaded
Mathure D; Ranpise H; Awasthi R; Pawar A
Assay Drug Dev Technol; 2022 Jul; 20(5):211-224. PubMed ID: 35771865
[TBL] [Abstract][Full Text] [Related]
14. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy.
Alam T; Pandit J; Vohora D; Aqil M; Ali A; Sultana Y
Expert Opin Drug Deliv; 2015 Feb; 12(2):181-94. PubMed ID: 25164097
[TBL] [Abstract][Full Text] [Related]
15. Nose to Brain Delivery of Astaxanthin-Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer's Disease: Preparation, in vitro and in vivo Evaluation.
Shehata MK; Ismail AA; Kamel MA
Int J Nanomedicine; 2023; 18():1631-1658. PubMed ID: 37020692
[TBL] [Abstract][Full Text] [Related]
16. Transdermal Delivery of Ondansetron Hydrochloride via Bilosomal Systems: In Vitro, Ex Vivo, and In Vivo Characterization Studies.
Ammar HO; Mohamed MI; Tadros MI; Fouly AA
AAPS PharmSciTech; 2018 Jul; 19(5):2276-2287. PubMed ID: 29845503
[TBL] [Abstract][Full Text] [Related]
17. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
18. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study.
Madane RG; Mahajan HS
Drug Deliv; 2016 May; 23(4):1326-34. PubMed ID: 25367836
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study.
Pokharkar V; Patil-Gadhe A; Palla P
Biomed Pharmacother; 2017 Oct; 94():150-164. PubMed ID: 28759752
[TBL] [Abstract][Full Text] [Related]
20. S-Protected thiolated nanostructured lipid carriers exhibiting improved mucoadhesive properties.
Arshad S; Masood-Ur-Rehman ; Hussain Asim M; Nazir I; Shahzadi I; Mousli M; Bernkop-Schnürch A
Int J Pharm; 2020 Sep; 587():119690. PubMed ID: 32738459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
